Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in daybreak: an open-label extension study of ozanimod phase 1-3 trials

被引：0

作者：

Selmaj, K. ^{[1
,2
]}

Steinman, L. ^{[3
]}

Comi, G. ^{[4
]}

Bar-Or, A. ^{[5
,6
]}

Arnold, D. ^{[7
,8
]}

Hartung, H. P. ^{[9
]}

Montalban, X. ^{[10
]}

Havrdova, E. ^{[11
]}

Sheffield, J. ^{[12
]}

Chen, T. ^{[12
]}

Minton, N. ^{[12
]}

Silva, D. ^{[12
]}

Kappos, L. ^{[13
,14
,15
,16
]}

Cohen, J. ^{[17
]}

Cree, B. ^{[18
]}

机构：

[1] Ctr Neurol, Lodz, Poland

[2] Univ Warmia & Mazury, Dept Neurol, Coll Med, Olsztyn, Poland

[3] Stanford Univ, Med Ctr, Beckman Ctr Mol Med, Stanford, CA 94305 USA

[4] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Milan, Italy

[5] Univ Penn, Perelman Sch Med, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA 19104 USA

[6] Univ Penn, Perelman Sch Med, Multiple Sclerosis Div, Philadelphia, PA 19104 USA

[7] McGill Univ, NeuroRx Res, Montreal, PQ, Canada

[8] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada

[9] Heinrich Heine Univ, Dusseldorf, Germany

[10] Hosp Univ Vall dHebron, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain

[11] Charles Univ Prague, Med Fac 1, Prague, Czech Republic

[12] Bristol Myers Squibb Co, Princeton, NJ USA

[13] Univ Hosp, Dept Med, Neurol Clin & Policlin, Basel, Switzerland

[14] Univ Hosp, Dept Biomed, Neurol Clin & Policlin, Basel, Switzerland

[15] Univ Hosp, Dept Clin Res, Neurol Clin & Policlin, Basel, Switzerland

[16] Univ Basel, Basel, Switzerland

[17] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH 44106 USA

[18] UCSF Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P0217

引用

页码：223 / 223

页数：1

共 50 条

[1] Long-term Efficacy of Ozanimod in Relapsing Multiple Sclerosis in DAYBREAK: An Open-Label Extension of the Phase 3 SUNBEAM and RADIANCE Trials
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-or, A.
Arnold, D. L.
Hartung, H-P
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Hetzer, J.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 473 - 474
[2] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Krakovich, A.
Sheffield, J. K.
Cheng, C. -Y.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
[3] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
Steinman, L.
Comi, G.
Bar-Or, A.
Selmaj, K. W.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Minton, N.
Janjua, A.
Huang, V.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
[4] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, K.
Hoogerheyde, J.
Afsari, S.
Sheffield, J. K.
Shi, F.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 617 - 618
[5] Hepatic safety of ozanimod in relapsing multiple sclerosis in the DAYBREAK open-label extension study
Selmaj, K.
Steinman, L.
Comi, G.
Bar-Or, A.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Minton, N.
Afsari, S.
Shi, F.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 608 - 609
[6] Ozanimod Efficacy in Relapsing Multiple Sclerosis Supported by Open-Label Long-Term Extension of Two Phase 3 Trials
Steinman, Lawrence
Comi, Giancarlo
Cree, Bruce A. C.
Bar-Or, Amit
Selmaj, Krzysztof W.
Arnold, Douglas L.
Hartung, Hans-Peter
Montalban, Xavier
Havrdova, Eva K.
Sheffield, James K.
Huang, Vivian
Silva, Diego
Kappos, Ludwig
Cohen, Jeffrey A.
NEUROLOGY, 2019, 92 (15)
[7] Update on Hepatic Safety of Ozanimod in Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Hartung, H. P.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Thorpe, A.
Riolo, J. V.
Krakovich, A.
Cheng, C. Y.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 325 - 326
[8] Safety patterns with ozanimod in phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
Selmaj, K. W.
Ziemssen, T.
Comi, G.
Hartung, H. P.
Singal, M.
Thorpe, A.
Riolo, J. V.
Cheng, C. Y.
Sheffield, J. K.
Krakovich, A.
Vermersch, P.
Cree, B. A. C.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 324 - 324
[9] Long-term Efficacy of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis in Two Phase 3 Trials and an Open-label Extension Trial
Cree, B. A.
Selmaj, K.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Cheng, C.
Riolo, J. V.
Silva, D.
Kappos, L.
Cohen, J. A.
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 55 - 56
[10] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
Cree, Bruce A. C.
Selmaj, Krzysztof W.
Steinman, Lawrence
Comi, Giancarlo
Bar-Or, Amit
Arnold, Douglas L.
Hartung, Hans-Peter
Montalban, Xavier
Havrdova, Eva K.
Sheffield, James K.
Minton, Neil
Cheng, Chun-Yen
Silva, Diego
Kappos, Ludwig
Cohen, Jeffrey A.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (12) : 1944 - 1962

← 1 2 3 4 5 →